Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Feb;91(2):289-97.
doi: 10.1038/clpt.2011.227. Epub 2011 Dec 28.

Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension

N Fujimura  1 , K Noma, T Hata, J Soga, T Hidaka, N Idei, Y Fujii, S Mikami, T Maruhashi, Y Iwamoto, Y Kihara, K Chayama, H Kato, J K Liao, Y Higashi; ROCK Study Group
Affiliations
Randomized Controlled Trial

Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension

N Fujimura et al. Clin Pharmacol Ther. 2012 Feb.

Abstract

Hypertension is associated with endothelial dysfunction and activated Rho-associated kinases (ROCKs). The purpose of this study was to evaluate the effects of the selective mineralocorticoid receptor blocker, eplerenone, on endothelial function and ROCK activity in patients with hypertension. The study was carried out over 48 weeks in 60 untreated patients with hypertension who were randomly assigned to eplerenone, nifedipine, and losartan groups. We evaluated the effects of each treatment on flow-mediated vasodilation (FMD) and ROCK activity in peripheral leukocytes. Eplerenone increased FMD and decreased leukocyte ROCK activity. Nifedipine decreased ROCK activity but did not alter FMD. Losartan increased FMD but did not alter ROCK activity. Hypotensive effects were similar in the three groups, as was nitroglycerin-induced vasodilation during the follow-up period. There were no significant differences between the groups with respect to other parameters. The study results show that eplerenone improves endothelial function and inhibits ROCK activity in patients with essential hypertension.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

J.K.L. is a consultant for Asahi-Kasei Pharmaceutical, Inc. The other authors declared no conflict of interest.

Figures

Figure 1
Figure 1
Flow-mediated vasodilation (FMD) in the eplerenone, nifedipine, and losartan groups before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment. *P < 0.05 vs. 0 weeks in the same group.
Figure 2
Figure 2
Representative measurements of the number of circulating progenitor cells (CPCs) by flow cytometry in a patient treated with eplerenone, a patient treated with nifedipine, and a patient treated with losartan before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (top). Comparison of the number of CPCs in patients in the eplerenone, nifedipine, and losartan groups before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (bottom). *P < 0.05 vs. 0 weeks in the same group.
Figure 3
Figure 3
Representative measurements of the migration of circulating progenitor cells (CPCs) labeled with DAPI by fluorescence in a patient treated with eplerenone, a patient treated with nifedipine, and a patient treated with losartan before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (top). Comparison of the migration of CPCs in patients in the eplerenone, nifedipine, and losartan groups before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (bottom). *P < 0.05 vs. 0 weeks in the same group. DAPI, 4’,6-diamidino-2-phenylindole; hpf, high-power field.
Figure 4
Figure 4
Representative data from western blot analysis for phospho-myosin-binding subunit (p-MBS), total-myosin-binding subunit (t-MBS), and β tublin in a patient treated with eplerenone, a patient treated with nifedipine, and a patient treated with losartan before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (top). ROCK activity (p-MBS/t-MBS) in patients in the eplerenone, nifedipine, and losartan groups before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (bottom). *P < 0.05 vs. 0 weeks in the same group.
See this image and copyright information in PMC

References

    1. Amano M et al. Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science 275, 1308–1311 (1997). - PubMed
    1. Uehata M et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389, 990–994 (1997). - PubMed
    1. Hall A Rho GTPases and the actin cytoskeleton. Science 279, 509–514 (1998). - PubMed
    1. Kimura K et al. Regulation of the association of adducin with actin filaments by Rho-associated kinase (Rho-kinase) and myosin phosphatase. J. Biol. Chem 273, 5542–5548 (1998). - PubMed
    1. Sauzeau V et al. Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle. J. Biol. Chem 275, 21722–21729 (2000). - PubMed

Publication types

MeSH terms